A new CAR T treatment has been delivered to the first myeloma Patient, using an off-the-shelf approach with donor T cells aimed at a new target, CS1. Most CAR T cell therapies in today's multiple myeloma clinical trials are "autologous," meaning they use the patient's own T cells. Many CAR T cell therapies in Phase [...]
This post first appeared on Page Not Found - The Myeloma Crowd, please read the originial post: here
